Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02375334 · ClinicalTrials.gov registry record
Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- 18
- Enrollment target
NCT02375334 is a clinical trial that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 18 participants.
The verdict
NCT02375334 was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- 18 participants
- Enrollment target
Study Summary
This research trial studies an adherence monitoring system in managing myelosuppression in patients with newly diagnosed malignant gliomas who are receiving temozolomide and radiation therapy. The development of an adherence monitoring system may help doctors more effectively utilize electronic medical records to manage myelosuppression during standard treatment with temozolomide and radiation therapy in patients with malignant gliomas.
Interventions
- OTHER Medical Chart Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02375334
The ClinicalTrials.gov registry entry for NCT02375334 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Medical Chart Review is the first listed.
NCT02375334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02375334 about?
NCT02375334 is a clinical study titled "Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy". This research trial studies an adherence monitoring system in managing myelosuppression in patients with newly diagnosed malignant gliomas who are receiving temozolomide and radiation therapy. The development of an adherence monitoring system may help doctors more effectively utilize electronic medi...
What is the current status of trial NCT02375334?
This trial is currently terminated. The enrollment target is 18 participants. The study started on 2015-02. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02375334?
The interventions under investigation include: Medical Chart Review (OTHER).
Who is sponsoring clinical trial NCT02375334?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.